Prediction of treatment response by anticitrullinated protein antibodies (ACPA) levels among patients with rheumatoid arthritis by Hernández Raquel, González Paz, Muñoz Alejandro, Marenco Jose

The reason to stop infliximab is clearly related to the existence of new alternatives: a correspondence analysis of biologics, reasons to stop, and time periods by Uceda Julia, Carmona Loreto, Muñoz Alejandro, Marenco Jose L

Clinical and functional effectiveness of anti-TNF therapy in patients with rheumatoid arthritis by Martínez-Pérez Rosalia, Uceda Julia, León Mario, Rodríguez Sergio, Muñoz Alejandro, Gallo Francisco, Velloso Maria, Marenco Jose

Clinical and economic efficiency to reduce dose etanercept and adalimumab in patients with rheumatoid arthritis by Martínez-Pérez Rosalía, Rodríguez-Montero Sergio, Muñoz Alejandro, Uceda Julia, León Mario, Gallo Francisco, Velloso Maria, Marenco José

Effectiveness of dose reduction of etanercept and adalimumab in patients with rheumatoid arthritis by Martínez-Pérez Rosalía, Rodríguez-Montero Sergio, Muñoz Alejandro, Uceda Julia, León Mario, Gallo Francisco, Velloso Maria, Marenco José